Skip to main content
S

SciVision Biotech Inc. — Investor Relations & Filings

Ticker · 1786 TW Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2026-04-28 Board/Management Inform…
Country TW Taiwan
Listing TW 1786

About SciVision Biotech Inc.

https://www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
公告本公司研發主管異動
Board/Management Information Classification · 1% confidence The document is a regulatory announcement on the public information observation station in Chinese, titled “公告本公司研發主管異動,” detailing the resignation/appointment of the R&D head (a senior management change). It is not a full report or earnings release but an announcement of management personnel changes, matching the “Board/Management Information” category (Code: MANG).
2026-04-28 Chinese
公告本公司「製造包含特安皮質醇之交聯透明質酸凝膠之方 法及交聯透明質酸凝膠」取得中華民國經濟部智慧財產局專利核 准審定書
Regulatory Filings Classification · 1% confidence The document is a formal announcement to the public information observatory by a listed company (科妍) about obtaining a patent approval certificate from the Taiwan Intellectual Property Office. It does not present financial results, governance rules, capital changes, or meeting materials, and clearly falls outside the specialized categories (e.g., earnings release, M&A, board changes). Hence it is best classified as a general regulatory filing (fallback category).
2026-04-15 Chinese
本公司” HYADERMIS”及” FACILLE”皮下填補劑通過 歐盟醫療器材法規MDR審查
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure from a listed company (科妍生物科技) announcing that its products passed EU MDR medical device regulation review. It is not an earnings release, financial report, dividend notice, management change, or other specific category. This falls under miscellaneous regulatory announcements. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-04-10 Chinese
115年3月背書保證與資金貸與
Regulatory Filings Classification · 0% confidence The document contains only a generic notice from the public information observatory system indicating no data is available and does not represent any specific report, announcement of a meeting, financial results, or other defined filing type. It serves as a miscellaneous regulatory placeholder. Therefore, it falls under the fallback category 'Regulatory Filings' (RNS).
2026-04-08 Chinese
115年3月營業收入
Regulatory Filings Classification · 1% confidence The document is a monthly revenue summary table provided via the Taiwan MOPS (Market Observation Post System). It shows net operating revenue for the current month and year‐to‐date comparing with last year, along with notes on IFRS adoption and calculation methods. It is a routine regulatory submission of operating data, not an AGM material, full annual or interim report, earnings release, management change notice, or other specific event document. There is no dedicated category for monthly revenue reports, so it falls under the general regulatory filings category (RNS).
2026-04-08 Chinese
115年03月內部人持股異動(事後)
Director's Dealing Classification · 1% confidence The document is a statutory insider shareholding disclosure listing directors, senior management, and their spouses/children with detailed shareholdings and any monthly changes. This fits the category of insider transactions or personal share dealings by company directors and executives. It is not a general financial report, but specifically a report of director dealings (DIRS).
2026-04-07 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.